The partnership will initially focus on co-developing various CDx claims in blood cancers for Kartos’ KRT-232. Credit: National Cancer Institute on Unsplash.

Illumina and Kartos Therapeutics have partnered to co-develop a next-generation sequencing-based TP53 companion diagnostic (CDx) for various hematologic indications.

The CDx will be based on Illumina’s genomic profiling assay, TruSight Oncology 500 (TSO 500), and be the first CDx to make use of TSO 500 with peripheral whole blood as the diagnostic sample type.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A research-use only pan-cancer assay, the TSO 500 system is designed for the detection of 523 known and emerging tumour biomarkers.

It uses both DNA and RNA from tumour samples to distinguish key variants, including small DNA variants, fusions and splice variants, which are essential to the development and progression of cancer.

Illumina chief medical officer Phil Febbo said: “With this partnership, Illumina will expand the TruSight Oncology offerings into hematologic malignancies.

“By leveraging our technology and harnessing the expertise at Kartos, we continue to advance Illumina’s commitment to develop standardised, globally distributable tools for precision oncology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership will initially focus on co-developing various CDx claims in blood cancers for Kartos’ KRT-232, a selective oral MDM2 inhibitor that triggers p53 and therefore causes the death of tumour cells in TP53 wild-type cancers.

KRT-232 is presently in the clinical development stage for various TP53 wild-type haematological malignancies and solid tumours.

Kartos chief medical officer and CEO Jesse McGreivy said: “Kartos is dedicated to developing novel, targeted therapeutics that meaningfully improve the lives of patients with cancer.

“This partnership will allow us to capitalise on TSO 500 as we explore the expanded use of KRT-232, which offers a unique mechanism to restore the function of p53, one of the most critical tumour suppressor proteins, resulting in apoptosis of malignant cells across a variety of hematologic and solid tumour types.”